RDHL earnings call for the period ending March 31, 2020.
News & Analysis: Redhill Biopharma
The company's opaganib shows promise in the fight against the SARS-CoV-2 coronavirus following the completion of a compassionate-use program.
RDHL earnings call for the period ending December 31, 2019.
The FDA just gave the company's latest treatment the green light.
Here's what you need to know about the upgrades and bullish price targets analysts recently slapped on these drugmakers.
Redhill's late-stage Crohn's disease drug hits the mark in a late-stage trial.